Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of 'Hold' by Analysts
Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) have been given a consensus rating of 'Hold' by the nine analysts that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold…
Architecting MedReach AI: Solving Data Rot and Regulatory Bottlenecks in Pharma Marketing
As we kick off Month 1 of our AI Software Development Capstone, I am thrilled to officially introduce the project I will be co-developing over the next five months: MedReach AI. In my role as the Project/Scrum Master and Backend Architect, I am…
aTyr Pharma (NASDAQ:ATYR) Stock Rating Upgraded by Wall Street Zen
aTyr Pharma (NASDAQ:ATYR - Get Free Report) was upgraded by analysts at Wall Street Zen from a 'sell' rating to a 'hold' rating in a research note issued on Sunday. Several other equities research analysts have also commented on the stock. Weiss…
NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen
NervGen Pharma (NASDAQ:NGEN - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a 'hold' rating to a 'sell' rating in a research note issued on Sunday. NGEN has been the topic of several other research reports. Zacks…
Watch The $360 Billion Market that Medicine Got Wrong for 20 Years
The $360 billion dollar women's health market is made of several categories that are often overlooked – one of which is menopause. The condition has gone largely unnoticed by pharma and biotech firms, employers, and investors, despite…
Here are the 3 big things we're watching in the stock market this week
The common thread linking this week's biggest market events is the state of the U.S. economy. The biggest day is Tuesday, when the nation's largest banks — JPMorgan, Bank of America and Citigroup, along with Club names Wells Fargo and…
BridgeBio: 'Strong Buy' Attruby Differentiation And Several NDA Submissions In Play (NASDAQ:BBIO)
BridgeBio Pharma (BBIO) remains a 'Strong Buy,' driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and international approvals for acoramidis, with Q1 2026…
Reed Jobs would rather talk about curing cancer than his last name
Reed Jobs is easy to like. He's motormouthed, self-deprecating, prone to video-game analogies, and clearly loves his work. He doesn't particularly want to discuss the fact that he is Steve Jobs's son, but he's not uptight about it, either. When our…
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
Mark Schoenberg, Chief Medical Officer, sold 10,000 ordinary shares of UroGen Pharma Ltd. (URGN 4.15%) on July 9, 2026, for a total value of $400,000, according to an SEC Form 4 filing. MetricValueTransaction value$400,000Shares…
Shareholders eye break-up as shares languish
The battle for Mayne Pharma was a headline grabber in 2025: a dramatic Treasurer intervention, a high-stakes manoeuvre at the Takeovers Panel and much hand-wringing over the application of material adverse change clauses. But since the collapse of…
Ventas: Ahead Of Q2 Results, Lots To Like About This Senior-Care REIT (NYSE:VTR)
Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…
Indian Army Agniveer Result 2026 out at joinindianarmy.nic.in; check merit list, next steps
3 min read New Delhi Make us preferred source on Google Indian Army Agniveer CEE 2026 Results Out: The Indian Army has declared the Agniveer Common Entrance Examination (CEE) Result 2026. Candidates who appeared for the online written examination…
Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors.
Investors pay careful attention to Ken Griffin's moves for one major reason: The founder of Citadel has an extremely solid track record of success. Citadel, which oversees $69 billion, in January was named the most profitable hedge fund ever…
First patients enrolled in record-breaking Ebola treatment trial in DRC
There is no approved drug to help the medical teams scrabbling to save lives in the Ebola outbreak in the Democratic Republic of the Congo – but there are hopes that could change within months as the first patients are enrolled in a…
Teva Pharmaceutical Industries (NYSE:TEVA) Cut to 'Hold' at Wall Street Zen
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a 'buy' rating to a 'hold' rating in a research report issued to clients and investors on Sunday. MarketBeat Week in…
Receive a Daily briefing on Pharma Industry News
Get Started